Status:
TERMINATED
Development of a Cabozantinib (Cabometyx) Symptom Management Application for Use in Patients With Renal Cancer
Lead Sponsor:
Duke University
Collaborating Sponsors:
Exelixis
Conditions:
Metastatic Renal Cell Carcinoma Treated With Cabozantinib
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this study is to develop an on-line electronic symptom management application that can ultimately be used to improve clinical outcomes in patients with mRCC treated with cabozantinib.
Detailed Description
This is a single-site, prospective technology-based, clinical trial. Nine patients with mRCC initiating cabozantinib therapy who meet subject eligibility criteria will be enrolled in this study. Subje...
Eligibility Criteria
Inclusion
- Patients \> 18 years of age Patients planning to start treatment with cabozantinib therapy for renal cancer.
- Technology requirement: The patient will need to have home wireless internet access for use of the software and technology in this study. The patient will need to already have or be willing to set up a Duke MyChart account.
Exclusion
- Non-English Speaking. Any patient who is not able to comprehend and operate the technology at the discretion of the enrolling provider.
Key Trial Info
Start Date :
August 21 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 16 2019
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT03867045
Start Date
August 21 2019
End Date
December 16 2019
Last Update
June 14 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Duke University Medical Center
Durham, North Carolina, United States, 27710
2
Duke Raleigh Hospital
Raleigh, North Carolina, United States, 27609